title: Prognostic model to predict survival following first-line chemotherapy in patients with metastatic gastric adenocarcinoma.
abstract: BACKGROUND
  This study was to devise a prognostic model for metastatic gastric cancer patients undergoing first-line chemotherapy.
  
  
  METHODS
  A retrospective analysis was carried out on 1455 gastric cancer patients, who received first-line chemotherapy from September 1994 to February 2005.
  
  
  RESULTS
  At multivariate level, poor prognostic factors were no previous gastrectomy [P = 0.003; relative risk (RR), 1.191; 95% confidence interval (CI) 1.061-1.338], albumin < 3.6 g/dl (P = or <0.001; RR, 1.245; 95% CI 1.106-1.402), alkaline phosphatase > 85 U/l (P = or <0.001; RR, 1.224; 95% CI 1.092-1.371), Eastern Cooperative Oncology Group performance status of two or more (P = or <0.001; RR, 1.690; 95% CI 1.458-1.959), the presence of bone metastases (P = 0.001; RR, 1.460; 95% CI 1.616-1.836), and the presence of ascites (P = or < 0.001; RR, 1.452; 95% CI 1.295-1.628). Of 1434 patients, 489 patients (34.1%) were categorized as low-risk group (zero to one factors), 889 patients (62.0%) as intermediate-risk group (two to four factors), and 56 patients (3.9%) as high-risk group (five to six factors). Median survival durations for low, intermediate, and high-risk groups were 12.5 months, 7.0 months, and 2.7 months, respectively.
  
  
  CONCLUSIONS
  This model should facilitate the individual patient risk stratification and thus, more appropriate therapies for each metastatic gastric cancer patient.
authors.affiliation: Division of Hematology/Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
authors.forename: J
authors.initials: J
authors.lastname: Lee
authors.forename: T
authors.initials: T
authors.lastname: Lim
authors.forename: J E
authors.initials: JE
authors.lastname: Uhm
authors.forename: K W
authors.initials: KW
authors.lastname: Park
authors.forename: S H
authors.initials: SH
authors.lastname: Park
authors.forename: S C
authors.initials: SC
authors.lastname: Lee
authors.forename: J O
authors.initials: JO
authors.lastname: Park
authors.forename: Y S
authors.initials: YS
authors.lastname: Park
authors.forename: H Y
authors.initials: HY
authors.lastname: Lim
authors.forename: T S
authors.initials: TS
authors.lastname: Sohn
authors.forename: J H
authors.initials: JH
authors.lastname: Noh
authors.forename: J S
authors.initials: JS
authors.lastname: Heo
authors.forename: C K
authors.initials: CK
authors.lastname: Park
authors.forename: S
authors.initials: S
authors.lastname: Kim
authors.forename: W K
authors.initials: WK
authors.lastname: Kang
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000145:classification; D005260:Female; D005500:Follow-Up Studies; D005743:Gastrectomy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D011379:Prognosis; D012189:Retrospective Studies; D013274:Stomach Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D016019:Survival Analysis; D013997:Time Factors; D016896:Treatment Outcome; D047368:Tumor Burden / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents